CARB-X is funding French biotech Mutabilis to develop a new class of antibacterials to treat infections caused by carbapenem-resistant Enterobacterales

  04 February 2021

CARB-X is awarding Mutabilis, a biopharmaceutical firm based in Romainville, France, up to US$6.4 million to develop a new drug to treat infections caused by Carbapenem-resistant Enterobacterales (CRE) bacteria. CRE has been dubbed the ‘nightmare bacteria’ by health officials because they cause deadly infections – often in healthcare settings – that cannot be effectively treated with existing antibiotics. Under the award agreement, Mutabilis will be eligible for an additional $5.8 million in further funding if certain project milestones are met, subject to available funds.

Further reading: CARB-X
Author(s): Jennifer Robinson
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support kindly provided by

Antimicrobial Resistance Fighter Coalition





Technology Database

Display your AMR Technology, Product and Service

 

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

 

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!